Device Trial Radar · NCT01170234
Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis
Last checked: Nov 19, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Aug 2010
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- Tufts Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 27, 2010
Design
- Study type
- Observational
- Who can join
- All sexes, from 7 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is currently no reliable, noninvasive biomarker for eosinophilic esophagitis (EoE), a chronic allergic diseases characterized by significant infiltration of eosinophils in the esophagus. Because eosinophils release nitric oxide, levels of exhaled nitric oxide (FeNO) are used routinely for guiding treatment in subsets of patients with asthma. FeNO levels are also elevated in immunological diseases that do not involve the airways. The investigators hypothesize that patients with EoE have elevated nitric oxide concentration in their exhaled breath and that changes in FeNO levels could be used to measure disease activity. The objective of this study is to determine the feasibility of using FeNO as a noninvasive surrogate marker for EoE disease activity. The investigators propose to measure serial exhaled nitric oxide (FeNO) levels on a group of patients with confirmed EoE, before, during and after the course of topical corticosteroid therapy to determine whether the level declines from pre-treatment level in individual patients.
Conditions
- Eosinophilic Esophagitis
Interventions
NIOX MINO® Airway Inflammation MonitorDevice
We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitisTime frame: 2 years
- Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitisTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tufts Medical Center
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.